Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease

N/ANot Yet RecruitingNCT07536490

Ankara University75 enrolled

Overview

The goal of this observational study is to investigate the relationship between sleep quality, cognitive functions, and disease severity in individuals with Parkinson's disease. The main question it aims to answer is: Is sleep quality associated with cognitive function and disease severity in individuals with Parkinson's disease? Participants will complete assessments of sleep quality, cognitive function, disease severity, and disease stage during a single evaluation session. Cognitive function will be evaluated using the Stroop Test, Clock Drawing Test, and Montreal Cognitive Assessment. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale, and disease stage will be determined using the Modified Hoehn and Yahr Scale.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Parkinson Disease

Eligibility

Sex: ALLMin age: 40 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 40 and 65 years * Diagnosis of Parkinson's disease confirmed by a neurologist * Modified Hoehn and Yahr stage between 1 and 3 * Montreal Cognitive Assessment (MoCA) score ≥21 Exclusion Criteria: * Difficulty in verbal communication * Use of walking aid * Severe visual impairment or additional neurological disorder * Presence of congestive heart failure * Any medical condition preventing participation

Locations (1)

Outcomes

Primary Outcomes

Sleep Quality

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.

Time frame: Baseline

Stroop Test

Cognitive flexibility and selective attention will be assessed using the Stroop Test. Completion time and error rates will be recorded, with longer times and higher error rates indicating poorer performance. Time Frame: Baseline

Time frame: Baseline

Clock Drawing Test

Visuospatial ability and executive function will be assessed using the Clock Drawing Test. Scores will be recorded based on standard scoring criteria, with lower scores indicating impaired performance.

Time frame: Baseline

Disease Severity

Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale. Higher scores indicate greater disease severity.

Time frame: Baseline

Secondary Outcomes

Montreal Cognitive Assessment

Global cognitive function will be assessed using the Montreal Cognitive Assessment. Total scores range from 0 to 30, with lower scores indicating greater cognitive impairment.

Time frame: Baseline

Disease Stage

Disease stage will be determined using the Modified Hoehn and Yahr Scale. Higher stages indicate more advanced disease.

Time frame: Baseline

Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts